Development of Fluid Intake App for Management of Fluid Intake During Hemodialysis
Fluid Intake App for Management of Volume Intake in Patients Receiving Chronic Hemodialysis Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject, upon briefing of the content of the present study, fully understanding and agreeing to its objective and having given written (dated and signed) informed consent form to take part in the study.
- Adult chronic hemodialysis patients who are at least 18 years of age
- Average interdialytic fluid gains of less than 4% of body weight for both weekdays and weekends for a 30 day period
- Access to a smartphone for use of the app and comfort with using apps on a regular basis
- Access to a smartphone running under either iOS or Android operating systems
- Sufficient knowledge and understanding of the English language to use the application available only in English (US) language
- Mental capacity to use and understand the fluid management app
- Willingness to share intake data collected with the research team
Exclusion Criteria:
- Scheduled for a living related renal transplant in the next four months
- Class III or IV heart failure
- Need for chronic oxygen therapy due to pulmonary disease
- Hospitalization within 30 days of entry into the study
- Current participation in a randomized clinical trial or in the exclusion period of another clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Vanguard
Participants in this arm will use the fluid intake app and take a survey to test the fluid intake monitoring app for both safety and design issues.
|
Use of fluid app to monitor intake of fluids
A survey will be used to assess the usability of the app (ease of use in general, ease of capturing fluid intake data, including the choice of pre-selected volumes for fluid containers, reasons for not using the app more frequently, the usefulness of the app notifications, ease of sending data to the study coordinator for review) as well as to collect recommendations for changes to the app itself.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amount of interdialytic weight gain
Time Frame: 1 month
|
The amount of weight gain as recorded by use of the app for each interdialytic period.
The association between the interdialytic weight gain and the fluid consumed will be assessed by a repeated measures analysis of variance with an unstructured covariance matrix.
|
1 month
|
|
Amount of fluid consumed
Time Frame: 1 month
|
The fluid consumed as recorded by use of the app for each interdialytic period.
The association between the interdialytic weight gain and the fluid consumed will be assessed by a repeated measures analysis of variance with an unstructured covariance matrix.
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients who experienced a 50% increase in fluid intake during app use
Time Frame: 1 month
|
This will be a safety evaluation to ensure that no participants had more than a 50% increase in fluid intake while using the app.
It will be described using descriptive statistics.
|
1 month
|
|
Number of days that the app was used
Time Frame: 1 month
|
This will be the determination of the number of days that the app was used.
|
1 month
|
|
Number of days that the app was used by day of the week
Time Frame: 1 month
|
Differences in app use by specific days of the week.
This is a sub analysis using days of the week.
|
1 month
|
|
Number of days that the app was used by dialysis or non-dialysis days
Time Frame: 1 month
|
Differences in app use by specific days of the week, including dialysis and non-dialysis days.
This is a sub analysis using dialysis versus non-dialysis days.
|
1 month
|
|
Ratio of weight of liquid intake
Time Frame: 1 month
|
Agreement between fluid intake and weight gain will be described using descriptive statistics by the ratio of weight of liquid intake between two visits over the interdialytic weight gain
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Michael Rocco, MD, Wake Forest University Health Sciences
Publications and helpful links
General Publications
- National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. Am J Kidney Dis. 2015 Nov;66(5):884-930. doi: 10.1053/j.ajkd.2015.07.015. Erratum In: Am J Kidney Dis. 2016 Mar;67(3):534.
- United States Renal Data System. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
- Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002 Dec 19;347(25):2010-9. doi: 10.1056/NEJMoa021583.
- Chan CT, Greene T, Chertow GM, Kliger AS, Stokes JB, Beck GJ, Daugirdas JT, Kotanko P, Larive B, Levin NW, Mehta RL, Rocco M, Sanz J, Schiller BM, Yang PC, Rajagopalan S; Frequent Hemodialysis Network (FHN) Trial Group. Determinants of left ventricular mass in patients on hemodialysis: Frequent Hemodialysis Network (FHN) Trials. Circ Cardiovasc Imaging. 2012 Mar;5(2):251-61. doi: 10.1161/CIRCIMAGING.111.969923. Epub 2012 Feb 23.
- Chan CT, Greene T, Chertow GM, Kliger AS, Stokes JB, Beck GJ, Daugirdas JT, Kotanko P, Larive B, Levin NW, Mehta RL, Rocco M, Sanz J, Yang PC, Rajagopalan S; Frequent Hemodialysis Network Trial Group. Effects of frequent hemodialysis on ventricular volumes and left ventricular remodeling. Clin J Am Soc Nephrol. 2013 Dec;8(12):2106-16. doi: 10.2215/CJN.03280313. Epub 2013 Aug 22.
- Assimon MM, Wenger JB, Wang L, Flythe JE. Ultrafiltration Rate and Mortality in Maintenance Hemodialysis Patients. Am J Kidney Dis. 2016 Dec;68(6):911-922. doi: 10.1053/j.ajkd.2016.06.020. Epub 2016 Aug 26.
- FHN Trial Group; Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010 Dec 9;363(24):2287-300. doi: 10.1056/NEJMoa1001593. Epub 2010 Nov 20. Erratum In: N Engl J Med. 2011 Jan 6;364(1):93.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB00048561
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Weight Gain
-
NCT02804061CompletedBirth Weight | Excessive Weight Gain in Pregnancy With Baby Delivered | Excessive Weight Gain in Pregnancy, First Trimester
-
NCT05712629CompletedBirth Weight | Pregnancy Weight Gain
-
NCT04992637CompletedObesity | Weight Gain, Maternal | Postpartum Weight Retention
-
NCT05590832CompletedGestational Weight Gain
-
NCT04330976CompletedGestational Weight Gain
-
NCT01803698WithdrawnGestational Weight Gain
-
NCT03154268Completed
-
NCT00455442Completed
-
NCT04294095CompletedGestational Weight Gain
Clinical Trials on Fluid intake app
-
NCT04194164Completed
-
NCT06954142RecruitingBronchopulmonary Dysplasia
-
NCT04363554CompletedChronic Kidney Diseases | Polycystic Kidney, Autosomal Dominant
-
NCT05931614Recruiting
-
NCT06044610Completed
-
NCT07400991RecruitingAcute Heart Failure (AHF)
-
NCT06212518Recruiting
-
NCT06937684CompletedPediatric Anesthesia | Ambulatory Surgical Procedures | Postoperative Nausea and Vomiting (PONV)
-
NCT04551729Completed